These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 10716499)

  • 1. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors.
    Huisman MT; Smit JW; Schinkel AH
    AIDS; 2000 Feb; 14(3):237-42. PubMed ID: 10716499
    [No Abstract]   [Full Text] [Related]  

  • 2. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors.
    Clayette P; Jorajuria S; Dormont D
    AIDS; 2000 Feb; 14(3):235-6. PubMed ID: 10716498
    [No Abstract]   [Full Text] [Related]  

  • 3. P glycoprotein in human immunodeficiency virus type 1 infection and therapy.
    Sankatsing SU; Beijnen JH; Schinkel AH; Lange JM; Prins JM
    Antimicrob Agents Chemother; 2004 Apr; 48(4):1073-81. PubMed ID: 15047504
    [No Abstract]   [Full Text] [Related]  

  • 4. Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter molecules.
    Hoggard PG; Back DJ
    Curr Opin Infect Dis; 2002 Feb; 15(1):3-8. PubMed ID: 11964899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular factors involved in the induction of resistance of HIV to antiretroviral agents.
    Turriziani O; Antonelli G; Dianzani F
    Int J Antimicrob Agents; 2000 Nov; 16(3):353-6. PubMed ID: 11091062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins.
    Shiraki N; Hamada A; Yasuda K; Fujii J; Arimori K; Nakano M
    Biol Pharm Bull; 2000 Dec; 23(12):1528-31. PubMed ID: 11145192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?
    Jones K; Bray PG; Khoo SH; Davey RA; Meaden ER; Ward SA; Back DJ
    AIDS; 2001 Jul; 15(11):1353-8. PubMed ID: 11504956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: theory and practice.
    Roberts NA; Craig JC; Sheldon J
    AIDS; 1998 Mar; 12(5):453-60. PubMed ID: 9543442
    [No Abstract]   [Full Text] [Related]  

  • 9. Combination therapy in the management of HIV infection.
    Vella S; Franca Pirillo M
    Methods Find Exp Clin Pharmacol; 1996; 18 Suppl C():23-6. PubMed ID: 9003571
    [No Abstract]   [Full Text] [Related]  

  • 10. Potential Tools for Eradicating HIV Reservoirs in the Brain: Development of Trojan Horse Prodrugs for the Inhibition of P-Glycoprotein with Anti-HIV-1 Activity.
    Agrawal N; Rowe J; Lan J; Yu Q; Hrycyna CA; Chmielewski J
    J Med Chem; 2020 Mar; 63(5):2131-2138. PubMed ID: 31505928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basic pharmacological interactions and how they may impact on one another.
    Benet L
    J Acquir Immune Defic Syndr; 2005 Mar; 38 Suppl 1():S22-3. PubMed ID: 15867606
    [No Abstract]   [Full Text] [Related]  

  • 12. Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies.
    Erickson JW; Gulnik SV; Markowitz M
    AIDS; 1999; 13 Suppl A():S189-204. PubMed ID: 10885776
    [No Abstract]   [Full Text] [Related]  

  • 13. May the drug transporter P glycoprotein affect the antiviral activity of human immunodeficiency virus type 1 proteinase inhibitors?
    Turriziani O; Di Marco P; Antonelli G; Dianzani F
    Antimicrob Agents Chemother; 2000 Feb; 44(2):473-4. PubMed ID: 10733463
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacodynamics and clinical use of anti-HIV drugs.
    Preston SL; Piliero PJ; Drusano GL
    Infect Dis Clin North Am; 2003 Sep; 17(3):651-74. PubMed ID: 14711082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scientific considerations for pharmacoenhancers in antiretroviral therapy.
    Arya V; Robertson SM; Struble KA; Murray JS
    J Clin Pharmacol; 2012 Aug; 52(8):1128-33. PubMed ID: 21712496
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical benefits of resistance assay for HIV-specific protease inhibitors: when to check and in whom?
    Aizawa S; Gatanaga H; Ida S; Sakai A; Tanaka M; Takahashi Y; Hirabayashi Y; Oka S
    AIDS; 1999 Jul; 13(10):1278-9. PubMed ID: 10416536
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeting P-Glycoprotein: Nelfinavir Reverses Adriamycin Resistance in K562/ADR Cells.
    Liu W; Meng Q; Sun Y; Wang C; Huo X; Liu Z; Sun P; Sun H; Ma X; Liu K
    Cell Physiol Biochem; 2018; 51(4):1616-1631. PubMed ID: 30497065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological exposure and the development of drug resistance in HIV.
    Hoetelmans R
    Antivir Ther; 2001; 6 Suppl 2():37-47. PubMed ID: 11678477
    [No Abstract]   [Full Text] [Related]  

  • 19. Indication for increasing prevalence of resistance mutations for protease inhibitors in therapy-naive HIV-1-positive German patients.
    Dietrich U; Raudonat I; Wolf E; Jäger H; Husak R; Orfanos CE; Knickmann M; Knechten H; von Briesen H; Ruppach H; Immelmann A
    AIDS; 1999 Nov; 13(16):2304-5. PubMed ID: 10563717
    [No Abstract]   [Full Text] [Related]  

  • 20. Update of the drug resistance mutations in HIV-1: 2004.
    Johnson VA; Brun-Vézinet F; Clotet B; Conway B; D'Aquila RT; Demeter LM; Kuritzkes DR; Pillay D; Schapiro JM; Telenti A; Richman DD
    Top HIV Med; 2004; 12(4):119-24. PubMed ID: 15516709
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.